BIAL's Zebinix Maintains EMA EU Approval, Continues Post-Market Safety Monitoring
EU Approval and Product Status
The European Medicines Agency (EMA) continues to manage Zebinix (eslicarbazepine acetate) from BIAL - Portela & Ca., S.A., a Portuguese unlisted pharmaceutical company, as a product with a valid EU marketing authorization. The drug is a prodrug that is converted in the body to eslicarbazepine, which stabilizes the inactivated state of voltage-gated sodium channels, thereby inhibiting repetitive neuronal firing. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on February 19, 2009, and the EU marketing authorization was granted on April 21, 2009, and the product is currently in the Marketed phase. The key focus of this EMA record is on the long-term accumulation of safety information and the ongoing management of the product label, rather than new approvals.
Indications and Clinical Evidence
Zebinix is indicated as monotherapy in newly diagnosed adults with partial-onset seizures and as adjunctive therapy to existing antiepileptic drugs. In children and adolescents over 6 years of age, it is approved as adjunctive therapy for partial-onset seizures, with or without secondary generalization. In the three pivotal clinical trials evaluated by the EMA, involving 1,050 adults, the mean monthly seizure frequency decreased from approximately 13 at baseline to 9.8 in the 800 mg group and 9.0 in the 1,200 mg group after 12 weeks, compared to 11.7 in the placebo group. The dose-dependent reduction in seizures and the convenience of once-daily administration provide a commercial differentiator in terms of compliance, particularly in patients with focal seizures who often take multiple medications.
Safety and Global Regulatory History
In adult clinical trials, approximately half of the patients experienced adverse events, with the most common being dizziness, somnolence, headache, and nausea. Serious skin reactions, including Stevens-Johnson syndrome, have been reported, and patients with second- or third-degree atrioventricular block are contraindicated due to the risk of cardiac conduction. In the United States, Aptiom (eslicarbazepine acetate) was approved by the FDA on November 8, 2013, for adjunctive therapy for partial-onset seizures in adults, and the indication was expanded to monotherapy in adults on August 27, 2015. The EMA's ongoing pharmacovigilance is a regulatory mechanism to reflect signals of harm in long-term prescribed products and to keep guidance for patients and healthcare professionals up to date.
Market and Competitive Landscape
The European market for antiepileptic drugs was estimated at USD 3.17 billion in 2024, providing a significant commercial basis for long-term maintenance therapies. In the initial monotherapy for focal seizures, Lamictal (lamotrigine) and Keppra (levetiracetam) are widely used, and Vimpat (lacosamide), Briviact (brivaracetam), Fycompa (perampanel), and Ontozry (cenobamate) also compete. In the NICE treatment algorithm, eslicarbazepine is positioned as a subsequent adjunctive option for focal seizures, so the sequence of prescriptions and generic competition limit market expansion. However, according to BIAL, Zebinix has been used in approximately 800,000 patients since its launch in 2009, and international markets accounted for 75% of the company's EUR 340 million in sales in 2023, making it a key cash-generating asset for the company's neurology business.
Zebinix, with approximately 800,000 patient experiences in the Marketed phase, is a key neurology asset for BIAL, and the maintenance of EMA approval and label management supports the continuity of European supply and existing cash flows. In the EUR 3.17 billion European market for antiepileptic drugs in 2024, lamotrigine and levetiracetam lead initial treatment, while lacosamide, brivaracetam, and cenobamate compete for subsequent prescriptions. For researchers and clinicians, it is important to continuously evaluate the benefits of once-daily administration, as well as the risks of serious skin reactions, dizziness, and atrioventricular block. While this is not an event involving new approvals or re-evaluation of clinical value, it provides a stable regulatory basis for BIAL's EUR 340 million in sales in 2023 and the long-term product life, although it is not a significant short-term catalyst for corporate value.
Source: EMA (ema)